Drug Profile

WPD 102

Alternative Names: WPD-102

Latest Information Update: 11 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator WPD Pharmaceuticals
Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

09 May 2024 Discontinued - Preclinical for Uveal melanoma in Poland (Intratumoural) before May 2024 (WPD Pharmaceuticals Website, June 2024)
28 Jan 2024 No recent reports of development identified for preclinical development in Uveal-melanoma in Poland (Intratumoural)
27 Dec 2019 Preclinical trials in Uveal melanoma in Poland (Intratumoural)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com